Recent Posts
- Ukraine recovery should be based on development of territorial communities, innovations, involvement of professional domestic community – results of ESUR forum 29.06.2023
- Ukraine repatriates five more seriously wounded Russian POWs 10.04.2023
- Rada intends to include history of Ukraine, foreign language in final certification for general secondary education 10.04.2023
- Rada terminates protocol on joint anti-terrorist measures in CIS territories for Ukraine 10.04.2023
- 100 Ukrainians, incl defenders of Mariupol, returned according to swap procedure – Yermak 10.04.2023
Lekhim sees net profit rise by almost 2.5 times, to UAH 534.145 mln, in 2021
KYIV. Jan 18 (Interfax-Ukraine) – Lekhim (Kyiv) in 2021 increased its net profit by 2.47 times compared to 2020, to UAH 534.145 million.
This was announced by the company in the information disclosure system of the National Securities and Stock Market Commission.
According to the report, the company’s net income in 2021 amounted to UAH 5.446 billion, which is 3.8 times more than a year earlier.
As reported, in 2020, Lekhim increased its net profit by 40.4% compared to 2019, to UAH 128.5 million.
In 2021, Lekhim, as an authorized representative of the Chinese manufacturer of the anti-COVID vaccine Sinovac Biotech in Ukraine, registered the Chinese vaccine against COVID-19 CoronaVac. Lekhim Group and Sinovac Biotech, which are partners, reached an agreement in negotiations that lasted 10 months on cooperation in the distribution and localization of production in Ukraine of a vaccine against the SARS-CoV-2 virus for a period of five years. According to the agreement, Lekhim is the official and exclusive supplier of the CoronaVac vaccine in Ukraine.
In 2022, Lekhim planned to start production of COVID and other vaccines at its own production facilities in Kharkiv.
Lekhim was founded in 1992. The nomenclature of the Lekhim group includes more than 200 types of medicines (tablets, capsules, ampoules, vials, suppositories, solutions).
